<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Protein-losing gastroenteropathy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Protein-losing gastroenteropathy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Protein-losing gastroenteropathy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jefferson N Brownell, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            J Thomas Lamont, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protein-losing gastroenteropathies are characterized by an excessive loss of serum proteins into the gastrointestinal tract, resulting in hypoproteinemia, edema, and, in some cases, pleural and pericardial effusions. The diagnosis of protein-losing gastroenteropathy should be considered in patients with hypoproteinemia in whom other causes, such as malnutrition, heavy proteinuria, and impaired protein synthesis due to liver disease, have been excluded.
        </p>
        <p>
         This topic will review the etiology, pathogenesis, clinical manifestations, diagnosis and management of protein-losing gastroenteropathy. Other causes of hypoalbuminemia are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4781.html" rel="external">
          "Overview of nutrient absorption and etiopathogenesis of malabsorption", section on 'Protein'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3084.html" rel="external">
          "Overview of heavy proteinuria and the nephrotic syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3566.html" rel="external">
          "Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)", section on 'Albumin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3413491955">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The normal gastrointestinal tract does not contribute significantly to the catabolism of plasma proteins, accounting for only approximately 10 percent of the normal turnover of albumin and gamma globulin [
         <a href="#rid1">
          1
         </a>
         ]. Once plasma proteins pass into the gastrointestinal tract, they are degraded rapidly to amino acids and reabsorbed into the portal circulation. The liver, as the primary site of plasma protein synthesis, can compensate for excess protein loss by increasing production by up to 2.5 times its normal rate [
         <a href="#rid2">
          2
         </a>
         ]. Protein-losing gastroenteropathy occurs when losses into the gastrointestinal tract exceed the liver's production capacity. This loss of serum proteins into the gastrointestinal tract occurs independent of molecular weight. Thus, the serum proteins most affected by this disrupted equilibrium are those with longer half-lives (ie, lower catabolic rate), like albumin, immunoglobulin A (IgA), IgG, IgM, ceruloplasmin, and fibrinogen. By contrast, there is little change in the serum concentrations of proteins with a rapid turnover rate (eg, transthyretin, insulin, IgE) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         In addition to proteins, other serum components that may also be lost in the gut include iron, lipids, and trace elements, many of which are protein-bound.
        </p>
        <p>
         Intestinal leakage of plasma proteins occurs via one of the following mechanisms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inflammatory exudation
         </strong>
         – Mucosal injury results in exudation of protein-rich fluids across the eroded epithelium. The degree of mucosal involvement typically correlates with the severity of protein loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased mucosal permeability
         </strong>
         – Altered integrity of the mucosa of the stomach, small bowel, and colon due to inflammatory, infiltrative, and genetic causes results in protein leakage into the lumen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intestinal loss of lymphatic fluid
         </strong>
         – Lymphatic obstruction, congenital abnormalities of the lymphatic system, or disorders of increased central venous pressure (eg, congestive heart failure or constrictive pericarditis) result in increased lymphatic pressure.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H776519286">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protein-losing gastroenteropathies can be caused by a diverse group of disorders  (
         <a class="graphic graphic_table graphicRef53419" href="/z/d/graphic/53419.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Erosive gastrointestinal diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enteral protein loss in patients with inflammatory bowel disease (eg, ulcerative colitis and Crohn disease) and gastrointestinal malignancies results from inflammatory exudation and absorptive loss from mucosal erosions and ulcerations. In addition, both Crohn disease and malignancy can cause lymphatic obstruction in the mesentery, leading to increased lymphatic pressure and the leakage of lymph into the gut lumen [
         <a href="#rid4">
          4
         </a>
         ]. Protein-losing gastroenteropathy also occurs in a subset of patients with colitis due to
         <em>
          Clostridioides difficile
         </em>
         infection but not in patients with asymptomatic colonization [
         <a href="#rid5">
          5,6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2699.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Nonerosive gastrointestinal diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of conditions, both congenital and acquired, can alter the integrity of the mucosa of the stomach, small bowel, or colon and cause protein leakage into the lumen  (
         <a class="graphic graphic_table graphicRef53419" href="/z/d/graphic/53419.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intestinal
         </strong>
         <strong>
          disease
         </strong>
         — Acquired protein-losing gastroenteropathy in celiac disease and tropical sprue is a consequence of the loss of villous structures and surface epithelium that facilitate the diffusion of plasma proteins between the cells. Other conditions that can be associated with protein-losing gastroenteropathy include allergic gastroenteropathy, eosinophilic gastroenteritis, collagenous colitis, systemic lupus erythematosus, and carbohydrate-deficient glycoprotein syndrome [
         <a href="#rid7">
          7-11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2536.html" rel="external">
          "Eosinophilic gastrointestinal diseases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4071.html" rel="external">
          "Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">
          "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Congenital disorders of systemic immune regulation and cell membrane protein function can cause increased intestinal permeability or decreased luminal substrate absorption resulting in intestinal protein loss. Biallelic loss-of-function mutations in
         <em>
          CD55
         </em>
         ,
         <em>
         </em>
         which
         <em>
         </em>
         encodes decay-accelerating factor (DAF) and regulates the complement cascade, have been associated with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE syndrome, or CD55-deficient PLE). Loss of DAF results in unchecked membrane attack complex deposition on erythrocytes and epithelial cells, causing intestinal injury [
         <a href="#rid12">
          12
         </a>
         ]. Additional rare genetic syndromes associated with gastrointestinal epithelial dysfunction include errors in lipid metabolism (mutations in
         <em>
          DGAT1
         </em>
         resulting in enterocyte toxicity [
         <a href="#rid13">
          13,14
         </a>
         ]); aberrant intestinal protein deposition (mutation in
         <em>
          ANTRX2
         </em>
         causing intestinal hyalinosis [
         <a href="#rid15">
          15
         </a>
         ]; and plasmalemma vesicle-associated protein deficiency (mutation in
         <em>
          PLVAP
         </em>
         [
         <a href="#rid16">
          16
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Giant
         </strong>
         <strong>
          hypertrophic
         </strong>
         <strong>
          gastropathy
         </strong>
         — Several proliferative, inflammatory, and infiltrative conditions are associated with large or giant mucosal folds in the stomach and protein-losing gastroenteropathy. Of these, Ménétrier disease is the most common gastric disorder associated with gastrointestinal protein loss [
         <a href="#rid17">
          17
         </a>
         ]. Increased intracellular permeability and wider tight junctions between cells leads to protein-rich exudates in the stomach. Other gastric causes of protein-losing gastroenteropathy include
         <em>
          Helicobacter pylori
         </em>
         gastritis and lymphocytic gastritis [
         <a href="#rid12">
          12,18-21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/34.html" rel="external">
          "Approach to the patient with large gastric folds", section on 'Ménétrier's disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/34.html" rel="external">
          "Approach to the patient with large gastric folds", section on 'Other causes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Amyloidosis
         </strong>
         — Patients with gastrointestinal amyloidosis can present with protein-losing gastroenteropathy due to mucosal infiltration [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2642.html" rel="external">
          "Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management", section on 'Gastrointestinal tract amyloidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Diseases with lymphatic obstruction/altered lymphatic flow
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intestinal lymphangiectasia is characterized by impaired small intestinal lymph drainage associated with dilated intestinal lymphatic channels. It can be due to primary malformation of intestinal lymphatics or secondary to other causes (eg, right-sided heart failure)  (
         <a class="graphic graphic_table graphicRef53419" href="/z/d/graphic/53419.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary
         </strong>
         <strong>
          intestinal
         </strong>
         <strong>
          lymphangiectasia
         </strong>
         — Primary intestinal lymphangiectasia is characterized by diffuse or localized ectasia of enteric lymphatics, often associated with lymphatic abnormalities elsewhere in the body [
         <a href="#rid23">
          23
         </a>
         ]. The ectatic lymphatics may be located in the mucosa, submucosa, or subserosa. In patients with lymphatic obstruction and particularly congenital lymphangiectasia, loss of lymphocytes into the gut can produce significant lymphocytopenia
         <strong>
         </strong>
         with detectable alterations in cellular immunity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The disease primarily affects children and young adults. The mean age of onset is approximately 11 years, but patients often have symptoms much earlier [
         <a href="#rid23">
          23
         </a>
         ]. Still, milder cases have been reported in older adults [
         <a href="#rid24">
          24
         </a>
         ]. Although most cases are sporadic, primary intestinal lymphangiectasia has been reported in multiple siblings of several families, suggesting that, at least in certain cases, it may have an underlying genetic cause. Intestinal lymphangiectasia has also been reported in association with the yellow-nail syndrome (triad of pulmonary disease, lymphedema, and slow-growing, yellow nails without a cuticle or lunula), Turner, Noonan, Hennekam, von Recklinghausen, and Klippel-Trenaunay syndromes [
         <a href="#rid16">
          16,25-29
         </a>
         ]. Several rare genetic syndromes have also been associated with protein-losing enteropathy. The pathogenesis in these cases is largely lymphatic obstruction leading to intestinal lymphangiectasia. The disorders include camptodactyly-arthropathy-coxa vara-pericarditis syndrome (mutations in
         <em>
          PRG4
         </em>
         [
         <a href="#rid30">
          30
         </a>
         ]); protein-losing enteropathy with intestinal lymphangiectasia and skeletal dysplasia (mutations in
         <em>
          FGFR3
         </em>
         [
         <a href="#rid31">
          31
         </a>
         ]); and tuberous sclerosis (mutation in
         <em>
          TSC2
         </em>
         [
         <a href="#rid32">
          32
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary
         </strong>
         <strong>
          intestinal
         </strong>
         <strong>
          lymphangiectasia
         </strong>
         — The most common causes of secondary intestinal lymphangiectasia are obstructive and include cardiac diseases and retroperitoneal lymph node enlargement due to malignancy or chemotherapeutic, infectious, or toxic substances  (
         <a class="graphic graphic_table graphicRef53419" href="/z/d/graphic/53419.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid33">
          33
         </a>
         ]. Cardiac conditions can lead to the development of secondary lymphangiectasia via an increase in central venous pressure, impeding drainage of the thoracic duct into the left subclavian vein. These include structural heart disease (eg, tricuspid insufficiency, congenital pulmonic stenosis, and atrial septal defect), constrictive pericarditis, cardiomyopathy, and single-ventricle physiology after surgical repair of complex congenital heart disease (eg, Fontan procedure) [
         <a href="#rid34">
          34-38
         </a>
         ]. Secondary intestinal lymphangiectasia has also been described in patients with portal hypertension or hepatic venous outflow obstruction after liver transplantation, and in congenital hepatic fibrosis due to phosphomannose isomerase deficiency [
         <a href="#rid39">
          39
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/95232.html" rel="external">
          "Management of complications in patients with Fontan circulation", section on 'Protein-losing enteropathy'
         </a>
         ). Malignancies including lymphomas and neuroblastoma can directly obstruct lymphatic drainage and cause upstream lymphatic dilation [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2821906469">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H2613615109">
         <span class="h2">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of protein-losing gastroenteropathy are highly variable and are determined by the underlying cause. Patients usually present with peripheral edema. Rarely, patients may present with gradually progressive dyspnea or painless abdominal distention due to symptomatic pleural effusions or ascites. Gastrointestinal symptoms of diarrhea, steatorrhea, abdominal pain, bloating, or flatulence may be present  (
         <a class="graphic graphic_table graphicRef53419" href="/z/d/graphic/53419.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Patients with primary intestinal lymphangiectasia present in childhood with edema, weight loss, intermittent diarrhea, nausea, and vomiting. Some patients develop steatorrhea. Peripheral edema is often present and may be pitting if it results from hypoalbuminemia, or asymmetric and nonpitting if it results from an underlying lymphatic conduction abnormality affecting the extremity. Chylothorax or chylous ascites may also be present in patients with a systemic disease or widespread lymphatic malformation. (See
         <a class="medical medical_review" href="/z/d/html/6698.html" rel="external">
          "Pleural fluid analysis in adults with a pleural effusion"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6696.html" rel="external">
          "Etiology, clinical presentation, and diagnosis of chylothorax"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1235.html" rel="external">
          "Chylous, bloody, and pancreatic ascites", section on 'Chylous ascites'
         </a>
         .)
        </p>
        <p>
         Patients with protein-losing gastroenteropathy secondary to cardiac disease can have profound hypoproteinemia with clinically significant nutritional and immunologic consequences. Clinical features include edema, ascites, pleural and pericardial effusions, failure to thrive, frequent infections, and in some cases, sepsis due to chronic hypogammaglobulinemia. Severe third-spacing of body fluids further compromises the already tenuous hemodynamics and intravascular volume loss. The combination of increased central venous pressures and low cardiac output places the patient at risk for thromboembolism. (See
         <a class="medical medical_review" href="/z/d/html/95232.html" rel="external">
          "Management of complications in patients with Fontan circulation", section on 'Thrombosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95232.html" rel="external">
          "Management of complications in patients with Fontan circulation", section on 'Protein-losing enteropathy'
         </a>
         .)
        </p>
        <p>
         Hypogammaglobulinemia and lymphocytopenia in patients with protein-losing gastroenteropathy are variable. The consequences of these apparent quantitative immune defects are unclear; while case reports exist suggesting a correlation between hypogammaglobulinemia and an increase in opportunistic infections, this observation is inconsistent [
         <a href="#rid42">
          42
         </a>
         ]. Furthermore, diseases typically associated with lymphocytopenia have not been observed, even in patients with low CD4+ counts [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2733801850">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main laboratory findings in PLE are reduced serum concentrations of albumin, gamma globulins (IgA, IgG, IgM), fibrinogen, cholesterol, transferrin, and ceruloplasmin  (
         <a class="graphic graphic_table graphicRef65661" href="/z/d/graphic/65661.html" rel="external">
          table 2
         </a>
         ). Deficiencies in minerals bound to albumin, ceruloplasmin, and other carrier proteins including zinc, copper, and iron may follow. Patients may have fat-soluble vitamin deficiencies.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protein-losing gastroenteropathy should be suspected in patients with edema and hypoalbuminemia in whom there is no other apparent cause of protein loss (eg, proteinuria), inadequate synthesis (eg, liver diseases), or supply (eg, protein malnutrition). The diagnosis of protein-losing gastroenteropathy is established by an increase in alpha-1 antitrypsin clearance.
        </p>
        <p>
         Alpha-1 antitrypsin is a glycoprotein synthesized in the liver and is the main component of the alpha-1 globulins. Alpha-1 antitrypsin has a higher molecular weight than albumin and is excreted intact in the stool because it is resistant to proteolysis and degradation in the intestinal lumen [
         <a href="#rid44">
          44,45
         </a>
         ]. The normal rate of alpha-1 antitrypsin excretion in the stool is less than 2.6 mg/g stool which reflects an intestinal clearance of less than 13 mL/day [
         <a href="#rid45">
          45,46
         </a>
         ]. Elevated alpha-1-antitrypsin clearance suggests increased enteral protein loss.
        </p>
        <p>
         The alpha 1-antitrypsin clearance test requires a 24-hour stool specimen and a serum sample for simultaneous measurement of alpha 1-antitrypsin in plasma.
        </p>
        <p>
         Alpha 1-antitrypsin clearance = (stool volume) x (stool alpha 1-antitrypsin)/ (serum alpha-1 antitrypsin)
        </p>
        <p>
         Diarrhea, even in the absence of protein-losing gastroenteropathy, can increase clearance of alpha-1 antitrypsin from plasma [
         <a href="#rid46">
          46
         </a>
         ]. Alpha-1 antitrypsin clearance values indicative of protein-losing enteropathy are greater than 27 mL/24 hours in patients without diarrhea and greater than 56 mL/day in patients with diarrhea.
        </p>
        <p>
         Alpha-1 antitrypsin is degraded by gastric acid with a pH below 3.5. In patients with suspected hypertrophic secretory gastropathy or in those with apparent gastrointestinal protein loss but a normal alpha-1 antitrypsin clearance, alpha-1 antitrypsin clearance should be performed while the patient is on acid suppression (eg,
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         40 mg once daily) [
         <a href="#rid45">
          45,47
         </a>
         ].
        </p>
        <p>
         Intestinal bleeding can significantly increase alpha-1 antitrypsin clearance rates [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Clearance of radiolabeled macromolecules (eg, 51Cr-labeled albumin, 125-I-labeled albumin, and 99mTc-labeled transferrin) is not routinely performed to diagnose protein-losing gastroenteropathy, as alpha-1 antitrypsin clearance is less expensive and less cumbersome to perform. The sensitivity and specificity of alpha-1 antitrypsin clearance as compared with 51Cr-labeled albumin are 93 and 90
         <em>
         </em>
         percent, respectively [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Random fecal alpha 1-antitrypsin concentration is not a reliable test for protein-losing gastroenteropathy. There is poor correlation between random stool alpha-1 antitrypsin concentrations and alpha-1 antitrypsin clearance measurements [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3915340355">
         <span class="h1">
          DETERMINING THE ETIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H706528998">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most patients, the etiology can be established from the history, physical examination, and laboratory data  (
         <a class="graphic graphic_table graphicRef53419" href="/z/d/graphic/53419.html" rel="external">
          table 1
         </a>
         ). The information gained from the initial evaluation will guide further testing. For example, patients with dyspnea on exertion should undergo echocardiography. (See
         <a class="local">
          'Additional testing'
         </a>
         below.)
        </p>
        <p>
         If patients have symptoms suggesting either an upper or lower gastrointestinal etiology, it is reasonable to start the evaluation with an upper endoscopy or colonoscopy, respectively. If patients do not undergo both an upper endoscopy and colonoscopy initially and no lesion is identified during the initial examination that explains the protein-losing gastroenteropathy, the other test (either an upper endoscopy or colonoscopy) should be performed. If both upper endoscopy and colonoscopy are negative, abdominal imaging should be pursued.
        </p>
        <p>
         For patients who are asymptomatic, we typically start with abdominal imaging to identify the underlying etiology. If the etiology is still not apparent, we perform endoscopic evaluation with both an upper endoscopy and colonoscopy.
        </p>
        <p>
         We perform a video capsule endoscopy if the underlying etiology continues to remain uncertain.
        </p>
        <p class="headingAnchor" id="H1961290320">
         <span class="h2">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The history should include the duration of symptoms and the presence of associated symptoms (eg, onset of edema in the hands and feet of a newborn girl is suggestive of Turner syndrome; the presence of shortness of breath may be due to heart failure or pleural effusion).
        </p>
        <p>
         A history of risk factors for protein-losing gastroenteropathy should be sought. This includes a history of recent travel to areas endemic for parasitic infections, recent antibiotic use that might predispose to an infection with
         <em>
          C. difficile,
         </em>
         chemotherapy, and NSAID exposure. Other important historical features include a history of inflammatory bowel disease, rheumatic disease (eg, systemic lupus erythematosus), gastrointestinal malignancy, or heart disease  (
         <a class="graphic graphic_table graphicRef53419" href="/z/d/graphic/53419.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Physical examination findings that may be suggestive of the underlying etiology include an elevated jugular venous pressure in a patient with right-sided heart failure. (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4946.html" rel="external">
          "Differentiating constrictive pericarditis and restrictive cardiomyopathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3465370309">
         <span class="h2">
          Laboratory studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory evaluation in patients with established protein-losing gastroenteropathy should include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count with differential
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum chemistries including electrolytes and aminotransferases
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Celiac serologies if endoscopy has not already been performed
        </p>
        <p>
        </p>
        <p>
         In addition, serum albumin, serum retinol, 25-hydroxyvitamin D, alpha-tocopherol, and prothrombin time should be obtained to assess the degree of hypoalbuminemia and to detect associated fat-soluble vitamin deficiencies. (See
         <a class="local">
          'Laboratory findings'
         </a>
         above.)
        </p>
        <p>
         Laboratory studies should also include stool examinations for infectious etiologies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ova and parasites
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stool
         <em>
          C. difficile
         </em>
         toxin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Giardia
         </em>
         stool antigen test, particularly if the patient has risk factors such as recent travel to endemic areas
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H142943003">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Computed tomography scan or magnetic resonance imaging of the abdomen may demonstrate lymphadenopathy suggestive of lymphoma, mesenteric panniculitis suggestive of sclerosing mesenteritis, and thickening of the bowel wall suggestive of inflammatory bowel disease or infectious colitis. In patients with primary intestinal lymphangiectasia, mucosal folds appear thickened and nodular-simulating stacked coins [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">
          "Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Abdomen and pelvis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2602.html" rel="external">
          "Sclerosing mesenteritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults", section on 'Imaging'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Imaging'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2699.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in adults: Clinical manifestations and diagnosis", section on 'Radiographic imaging'
         </a>
         .)
        </p>
        <p>
         Dynamic contrast magnetic resonance lymphangiography (DCMRL) is increasingly available. Using this technique, direct percutaneous lymphatic vessel access with targeted contrast injections can effectively map segments of the lymphatic system and localize specific lymphatic abnormalities [
         <a href="#rid49">
          49,50
         </a>
         ]. In some patients with protein-losing enteropathy (PLE), intrahepatic lymphatic duct contrast injection reveals direct communication between lymphatic vessels and the duodenal lumen [
         <a href="#rid51">
          51
         </a>
         ]. Extravasation of contrast into the duodenal lumen confirms the PLE diagnosis and localizes the site of enteric protein leak.
        </p>
        <p>
         In patients with intestinal lymphangiectasia, abnormal intestinal lymphatics can also be demonstrated by contrast lymphangiography and nuclear scintigraphy [
         <a href="#rid52">
          52,53
         </a>
         ]. However, these tests are rarely performed and offer little additional information once an alpha-1 antitrypsin clearance test has been performed. Neither is particularly effective at localizing the site of enteric leak, and the value of these techniques in routine clinical practice is not established. Nuclear scintigraphy has been reported to demonstrate the abnormal intestinal lymphatics by using a technetium-labeled tracer (usually albumin or dextran) and assessing intestinal leakage [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1516970064">
         <span class="h2">
          Endoscopy and biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with hyperplastic gastropathies (eg, Ménétrier disease, hyperplastic hypersecretory gastropathy, and Zollinger-Ellison syndrome) have enlarged gastric folds or rugae on endoscopy. Patients with Zollinger-Ellison syndrome may have multiple peptic ulcers. (See
         <a class="medical medical_review" href="/z/d/html/34.html" rel="external">
          "Approach to the patient with large gastric folds", section on 'Ménétrier's disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">
          "Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis", section on 'Endoscopic features'
         </a>
         .)
        </p>
        <p>
         In patients with primary intestinal lymphangiectasia, scattered white spots (snowflake-like appearance) overlie the small intestinal mucosa [
         <a href="#rid54">
          54,55
         </a>
         ]. Consumption of a high-fat meal the evening before endoscopic evaluation can make these findings more apparent. Histopathologic examination reveals markedly dilated lymphatics that are most apparent in the tips of the villi. In addition, electron microscopy reveals dilated lymphatic vessels filled with chylomicrons and precipitated lymph proteins. These findings are also present in the dilated intraepithelial gaps extending from the basolateral membrane to the apical region of the epithelium.
        </p>
        <p class="bulletIndent1">
         Endoscopic findings in patients with inflammatory bowel disease and microscopic colitis are nonspecific, and biopsies of the colon are necessary to establish the diagnosis and rule out other causes of colitis. Histopathological findings in patients with inflammatory bowel disease and microscopic colitis are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults", section on 'Endoscopy and biopsy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Endoscopy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4071.html" rel="external">
          "Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management", section on 'Endoscopy and biopsy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1633370367">
         <span class="h2">
          Additional testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional testing should be guided by the signs and symptoms and results of prior evaluation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoantibody testing and related studies
         </strong>
         – In patients with features in their medical history, physical examination, or other testing (eg, serum creatinine) that suggests a possible systemic rheumatic disorder, we obtain serologic and other studies based upon the specific condition suspected from the features that are present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Echocardiogram
         </strong>
         – In patients with clinical suspicion of cardiac involvement, such as signs or symptoms of heart failure, we obtain an echocardiogram.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2627810906">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of protein-losing gastroenteropathy is broad and varies based on the clinical presentation. The differential diagnosis of hypoalbuminemia and edema includes renal disease with proteinuria, liver diseases leading to inadequate protein synthesis, and protein malnutrition. (See
         <a class="medical medical_review" href="/z/d/html/2309.html" rel="external">
          "Pathophysiology and etiology of edema in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3084.html" rel="external">
          "Overview of heavy proteinuria and the nephrotic syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Goals of therapy for patients with protein-losing gastroenteropathy include maximizing nutritional status and quality of life by reducing symptoms and sequela. Long-term management of protein-losing gastroenteropathy consists of two components:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dietary therapy to improve nutrition
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of the underlying disease when present
        </p>
        <p>
        </p>
        <p>
         Serum protein levels (albumin, immunoglobulins, transferrin) should be monitored regularly, with the goal to bring these values as close to normal as possible. The percentage of patients in whom hypoalbuminemia can be corrected varies considerably and depends upon the type and severity of the underlying disease. In patients with severe erosive disease or intestinal dysmotility, when protein requirements can only be partially met by oral feeding and oral supplements, additional calories and protein can be delivered parenterally. At the same time, normal serum albumin concentrations are not necessary for symptom improvement or resolution, and the goal of care should be to safely maintain quality of life rather than prioritize normal serum protein concentrations. (See
         <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">
          "Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription", section on 'Calculating calorie and protein requirements in adequately nourished patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Dietary therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mainstay of dietary therapy is a low-fat, high-protein, high medium-chain triglyceride (MCT) diet. This approach is associated with favorable effects on hypoalbuminemia, gastrointestinal symptoms, and growth [
         <a href="#rid48">
          48,56,57
         </a>
         ]. Patients should work closely with an experienced dietitian.
        </p>
        <p>
         The diet in patients with protein-losing gastroenteropathy should be low in long-chain fatty acids, generally present as long-chain triglycerides (LCTs). The theoretical basis for a low LCT diet is that the reduction in intake of LCTs reduces lymphatic flow (driven by chylomicron export from intestinal epithelial cells into lacteals) and pressure in the lymphatic system, thus decreasing the quantity of enteric lymph leakage. There is no "one size fits all" diet, and different patients will likely tolerate different thresholds of LCT intake. Adjustments over time are usually necessary to find the appropriate balance between dietary restriction, symptom management, and quality of life.
        </p>
        <p>
         In our practice, we start by limiting LCT intake to &lt;10 percent of total calories. This typically translates to 10 to 20 g/day in children 1 to 10 years of age, and 15 to 25 g/day in people &gt;10 years of age. Fat intake should be spread throughout the day, divided among meals and snacks, to minimize lymphatic flow from fat boluses. While reduction in LCT intake may decrease enteric protein loss, such a severe calorie restriction increases the risk of malnutrition and micronutrient deficiencies.
        </p>
        <p>
         Calories lost from LCT restriction can be replaced with MCTs, which include saturated fatty acids of 6 to 12 carbon atoms. As opposed to LCTs, MCTs are not re-esterified in the intestinal epithelial cells and are exported directly to the portal circulation rather than the lymphatic circulation. Various preparations of MCTs are commercially available as purified natural or synthetic oil, a modular powder, or as part of an oil blend. Some natural oils contain high percentages of MCT relative to LCT, including palm kernel and coconut oils; however, the LCT content in these oils may exceed tolerable levels. Excessive intake of MCTs can cause gastrointestinal distress, including nausea and diarrhea, so starting at a low dose and titrating up to a tolerable provision is advised. We typically start at 0.5 g/kg/day in children and 50 g/day in adults, divided into two to three doses over the day to minimize adverse effects. These doses can be titrated up to 1 to 1.5 g/kg/day and 100 g/day, respectively, based on patient tolerance.
        </p>
        <p>
         In addition to making up the calorie deficit from an LCT-restricted diet, adequate essential fatty acids must be provided. Alpha-linolenic acid and linoleic acid are the essential long-chain polyunsaturated fatty acids [
         <a href="#rid58">
          58
         </a>
         ]. While absolute requirements of alpha-linolenic acid and linoleic acid are minimal, 4 and 1 percent of overall calories, respectively, they are not commercially available individually and must be obtained from natural oils [
         <a href="#rid59">
          59
         </a>
         ]. These are available in highest concentrations in flax seeds, walnuts, salmon, sardines, and soybeans, as well as in corn, canola, and safflower oils. In patients who cannot tolerate enteral supplementation, topical applications have been attempted to prevent and treat essential fatty acid deficiency with mixed results [
         <a href="#rid60">
          60-62
         </a>
         ]. However, this approach should be used as a last resort, to be considered in light of the patient's overall clinical status and deficiency risk.
        </p>
        <p>
         Patients with PLE are at risk of fat-soluble vitamin deficiency from enteric loss of carrier proteins. In addition, fat-soluble vitamins require emulsification with bile salts and LCTs at the mucosal surface for efficient absorption into the enterocyte. Patients with PLE often require large doses of fat-soluble vitamin supplementation to overcome the poor absorption efficiency. When possible, these vitamins should be supplemented in water-miscible or water-soluble forms, and serum concentrations should be monitored every three to six months. Additional trace element and mineral supplementation may be required to achieve normal serum concentrations, particularly iron, zinc, and copper.
        </p>
        <p>
         Protein requirements are increased in patients with PLE to 3 g/kg in children and adolescents and 1.5 to 3 g/kg/day in adults [
         <a href="#rid63">
          63,64
         </a>
         ]. The diet can be supplemented by commercially available protein formulas. Isolated protein supplements (eg, Casec, ProMod, BeneProtein) are a reliable source of fat-free dietary protein, but are expensive and may be unpalatable. Supplements that provide both protein and nonprotein calories (eg, Ensure, Isocal, Peptamen, and PediaSure) may be more palatable. Whey protein supplements can be added to skim milk or starchy foods to increase protein intake.
        </p>
        <p>
         For the infant with PLE, a number of formulas are commercially available that have MCT as the primary fat source (including Enfaport, Monogen). For older children and adults, available formulas are either fat-free (ProViMin, Tolerex, Vivonex T.E.N.) or low fat/high MCT (Lipistart, Portagen, Vivonex Pediatric). Most of these formulas are poorly tolerated due to taste and can be expensive. As not all of these formulas are otherwise nutritionally complete, their use should be supervised by an experienced dietitian.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Treatment of the underlying disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of the underlying disease has been associated with regression of PLE. As examples, immunosuppressive therapy in patients with inflammatory diseases (eg, systemic lupus erythematosus, inflammatory bowel disease, gut graft versus host disease), pericardiectomy in patients with constrictive pericarditis, and repair of cardiac abnormalities and hepatic venous outflow obstruction [
         <a href="#rid8">
          8,65-70
         </a>
         ]. The treatments used for most specific disorders are described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/140886.html" rel="external">
          "Constrictive pericarditis: Management and prognosis", section on 'Treatment of late (chronic) disease'
         </a>
         .)
        </p>
        <p>
         Monoclonal antibodies targeting C5, a key complement protein in the first step of membrane attack complex formation, appear to have efficacy in treating patients with CD55-deficient PLE (CHAPLE syndrome).
         <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">
          Eculizumab
         </a>
         , a monoclonal antibody targeting C5, used in the treatment of atypical hemolytic uremic syndrome, myasthenia gravis, and paroxysmal nocturnal hemoglobinuria, has been used in patients with CHAPLE syndrome. In one study that included three patients in a single family with CHAPLE syndrome, the use of eculizumab was associated with improvement in serum albumin and total protein concentrations and diarrhea after 100 days of treatment [
         <a href="#rid71">
          71
         </a>
         ].
         <a class="drug drug_general" data-topicid="142480" href="/z/d/drug information/142480.html" rel="external">
          Pozelimab
         </a>
         , a C5 inhibitor, has been approved to treat patients ≥1 year of age with CD55-deficient PLE (CHAPLE syndrome) [
         <a href="#rid72">
          72
         </a>
         ]. In an ongoing single-arm phase II/III clinical trial (NCT04209634) of 10 subjects with CHAPLE syndrome with symptomatic hypoalbuminemia (mean baseline serum albumin concentration of 2.2 g/dL plus either diarrhea, abdominal pain, peripheral edema, or facial edema), all 10 subjects achieved normalization of albumin by week 12 of treatment with pozelimab and maintained serum albumin concentrations within the normal range through at least 72 weeks. Improvements were also reported in serum IgG concentrations and total iron-binding capacity. While FDA approval of pozelimab is promising, long-term safety data are needed. (See
         <a class="local">
          'Nonerosive gastrointestinal diseases'
         </a>
         above.)
        </p>
        <p>
         Surgery (eg, intestinal resection or anastomosis of abnormal lymphatics to venous channels) should be reserved for patients with localized and refractory intestinal disease [
         <a href="#rid48">
          48,73
         </a>
         ]. However, these approaches are not always feasible.
        </p>
        <p>
         The somatostatin analogue,
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         , has been associated with an improvement in protein-losing gastroenteropathy in case reports of patients with Menetrier disease (100 micrograms twice daily) and primary intestinal lymphangiectasia (200 micrograms twice daily) [
         <a href="#rid74">
          74,75
         </a>
         ]. However, there is insufficient evidence to routinely support its use. The mechanism by which octreotide decreases PLE is unclear but likely relates to the reduction in splanchnic blood flow, and thus reduced lymphatic pressure in the capillary bed.
        </p>
        <p class="headingAnchor" id="H62464130">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protein-losing gastroenteropathies are characterized by an excessive loss of serum proteins into the gastrointestinal tract. Protein-losing gastroenteropathies can be caused by a diverse group of disorders  (
         <a class="graphic graphic_table graphicRef53419" href="/z/d/graphic/53419.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intestinal leakage of plasma proteins results from inflammatory exudation due to mucosal injury; increased mucosal permeability due to altered integrity of the mucosa of the stomach, small bowel, and colon; and increased lymphatic pressure in the gut. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical manifestations of protein-losing gastroenteropathy are highly variable and are determined in part by the underlying cause  (
         <a class="graphic graphic_table graphicRef65661" href="/z/d/graphic/65661.html" rel="external">
          table 2
         </a>
         ). Patients usually present with peripheral edema. Rarely patients may present with gradually progressive dyspnea or painless abdominal distention due to symptomatic pleural effusions or ascites. Gastrointestinal symptoms of diarrhea, steatorrhea, abdominal pain, bloating, or flatulence may be present in patients with underlying small bowel or colonic disease. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The main laboratory findings in protein-losing enteropathy are reduced serum concentrations of albumin, gamma globulins (IgA, IgG, IgM), fibrinogen, cholesterol, transferrin, and ceruloplasmin. Patients may have fat-soluble vitamin deficiencies due to their underlying small bowel disease. (See
         <a class="local">
          'Laboratory findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protein-losing gastroenteropathy should be suspected in patients with edema and hypoalbuminemia in whom there is no other apparent cause of protein loss (eg, proteinuria), inadequate synthesis (eg, liver diseases), or supply (eg, protein malnutrition). The diagnosis of protein-losing gastroenteropathy is established by an increase in alpha-1 antitrypsin clearance. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Once the diagnosis of protein-losing gastroenteropathy is established, the underlying etiology should be determined. In most patients, the diagnosis can be established from the history, physical examination, and laboratory data. The information gained from the initial evaluation will guide further testing. (See
         <a class="local">
          'Determining the etiology'
         </a>
         above and
         <a class="local">
          'Our approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of protein-losing gastroenteropathy consists of dietary therapy to improve nutrition and treatment of the underlying disease. The mainstay of dietary therapy is a low-fat, high-protein, medium-chain triglyceride diet. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2843806242">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff thank Vladan Milovic, MD, PhD, Richard J Grand, MD, and David A Piccoli, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Schmidt PN, Blirup-Jensen S, Svendsen PJ, Wandall JH. Characterization and quantification of plasma proteins excreted in faeces from healthy humans. Scand J Clin Lab Invest 1995; 55:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schomerus H, Mayer G. Synthesis rates of albumin and fibrinogen in patients with protein-losing enteropathy and in a patient recovering from protein malnutrition. Digestion 1975; 13:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takeda H, Ishihama K, Fukui T, et al. Significance of rapid turnover proteins in protein-losing gastroenteropathy. Hepatogastroenterology 2003; 50:1963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acciuffi S, Ghosh S, Ferguson A. Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss. Aliment Pharmacol Ther 1996; 10:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybolt AH, Bennett RG, Laughon BE, et al. Protein-losing enteropathy associated with Clostridium difficile infection. Lancet 1989; 1:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dansinger ML, Johnson S, Jansen PC, et al. Protein-losing enteropathy is associated with Clostridium difficile diarrhea but not with asymptomatic colonization: a prospective, case-control study. Clin Infect Dis 1996; 22:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stark ME, Batts KP, Alexander GL. Protein-losing enteropathy with collagenous colitis. Am J Gastroenterol 1992; 87:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebert EC, Hagspiel KD. Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol 2011; 45:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molina JF, Brown RF, Gedalia A, Espinoza LR. Protein losing enteropathy as the initial manifestation of childhood systemic lupus erythematosus. J Rheumatol 1996; 23:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaeken J, Vanderschueren-Lodeweyckx M, Casaer P. Familial psychomotor retardation with markedly fluctuating serum prolactin, FSH and GH levels, partial TBG-deficiency, increased serum arylsulfatase A and increased CSF protein: a new syndrome. Pediatr Res 1980; 14:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hendriksz CJ, McClean P, Henderson MJ, et al. Successful treatment of carbohydrate deficient glycoprotein syndrome type 1b with oral mannose. Arch Dis Child 2001; 85:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farahat K, Hainaut P, Jamar F, et al. Lymphocytic gastritis: an unusual cause of hypoproteinaemia. J Intern Med 1993; 234:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephen J, Vilboux T, Haberman Y, et al. Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations. Eur J Hum Genet 2016; 24:1268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rijn JM, Ardy RC, Kuloğlu Z, et al. Intestinal Failure and Aberrant Lipid Metabolism in Patients With DGAT1 Deficiency. Gastroenterology 2018; 155:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schussler E, Linkner RV, Levitt J, et al. Protein-losing enteropathy and joint contractures caused by a novel homozygous ANTXR2 mutation. Adv Genomics Genet 2018; 8:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malek NP, Ocran K, Tietge UJ, et al. A case of the yellow nail syndrome associated with massive chylous ascites, pleural and pericardial effusions. Z Gastroenterol 1996; 34:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly DG, Miller LJ, Malagelada JR, et al. Giant hypertrophic gastropathy (Ménétrier's disease): pharmacologic effects on protein leakage and mucosal ultrastructure. Gastroenterology 1982; 83:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayerdörffer E, Ritter MM, Hatz R, et al. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori--is Helicobacter pylori a pathogenic factor in Ménétrier's disease? Gut 1994; 35:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groisman GM, George J, Berman D, Harpaz N. Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori. Am J Gastroenterol 1994; 89:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada M, Sumazaki R, Adachi H, et al. Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori. Eur J Pediatr 1997; 156:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolber RA, Owen DA, Anderson FH, Freeman HJ. Lymphocytic gastritis and giant gastric folds associated with gastrointestinal protein loss. Mod Pathol 1991; 4:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki C, Higaki S, Nishiaki M, et al. 99mTc-HSA-D scintigraphy in the diagnosis of protein-losing gastroenteropathy due to secondary amyloidosis. J Gastroenterol 1997; 32:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Umar SB, DiBaise JK. Protein-losing enteropathy: case illustrations and clinical review. Am J Gastroenterol 2010; 105:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cappell MS, Edhi A, Amin M. Case report of primary intestinal lymphangiectasia diagnosed in an octogenarian by ileal intubation and by push enteroscopy after missed diagnosis by standard colonoscopy and EGD. Medicine (Baltimore) 2018; 97:e9649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atton G, Gordon K, Brice G, et al. The lymphatic phenotype in Turner syndrome: an evaluation of nineteen patients and literature review. Eur J Hum Genet 2015; 23:1634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joyce S, Gordon K, Brice G, et al. The lymphatic phenotype in Noonan and Cardiofaciocutaneous syndrome. Eur J Hum Genet 2016; 24:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hennekam RC, Geerdink RA, Hamel BC, et al. Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation. Am J Med Genet 1989; 34:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mifepristone/gemeprost to abort early pregnancy. Drug Ther Bull 1993; 31:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooreman M, Lübke H, Wienbeck M, Strohmeyer G. [Exudative enteropathy in Klippel-Trenaunay syndrome]. Klin Wochenschr 1988; 66:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters B, Schuurs-Hoeijmakers JH, Fuijkschot J, et al. Protein-losing enteropathy in camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome. Pediatr Rheumatol Online J 2016; 14:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang C, Dehner LP. Protein-losing enteropathy with intestinal lymphangiectasia in skeletal dysplasia with Lys650Met mutation. Am J Med Genet A 2016; 170:2993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollack SF, Geffrey AL, Thiele EA, Shah U. Primary intestinal lymphangiectasia treated with rapamycin in a child with tuberous sclerosis complex (TSC). Am J Med Genet A 2015; 167A:2209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liston K, Jeffers M, Hogan J, McHugh J. Protein-losing enteropathy in association with gastrointestinal IgM deposition in Waldenström macroglobulinaemia. Br J Haematol 2022; 198:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meadows J, Jenkins K. Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment. Cardiol Young 2011; 21:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller C, Globits S, Glogar D, et al. Constrictive pericarditis without typical haemodynamic changes as a cause of oedema formation due to protein-losing enteropathy. Eur Heart J 1991; 12:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkinson P, Pinto B, Senior JR. Reversible protein-losing enteropathy with intestinal lymphangiectasia secondary to chronic constrictive pericarditis. N Engl J Med 1965; 273:1178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldt RH, Driscoll DJ, Offord KP, et al. Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 1996; 112:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobs JD, Swanson PE, Brentnall T. Protein Losing Enteropathy due to Gut Plasmacytoma Polyposis. Am J Gastroenterol 2019; 114:1834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Koning TJ, Dorland L, van Berge Henegouwen GP. Phosphomannose isomerase deficiency as a cause of congenital hepatic fibrosis and protein-losing enteropathy. J Hepatol 1999; 31:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konar A, Brown CB, Hancock BW, Moss S. Protein losing enteropathy as a sole manifestation of non-Hodgkin's lymphoma. Postgrad Med J 1986; 62:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico MA, Weiner M, Ruzal-Shapiro C, et al. Protein-losing enteropathy: an unusual presentation of neuroblastoma. Clin Pediatr (Phila) 2003; 42:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hlavackova E, Liska M, Jicinska H, et al. Secondary Combined Immunodeficiency in Pediatric Patients after the Fontan Operation: Three Case Reports. Int Arch Allergy Immunol 2016; 170:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magdo HS, Stillwell TL, Greenhawt MJ, et al. Immune Abnormalities in Fontan Protein-Losing Enteropathy: A Case-Control Study. J Pediatr 2015; 167:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernier JJ, Florent C, Desmazures C, et al. Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin. Lancet 1978; 2:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Florent C, L'Hirondel C, Desmazures C, et al. Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy. Gastroenterology 1981; 81:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strygler B, Nicar MJ, Santangelo WC, et al. Alpha 1-antitrypsin excretion in stool in normal subjects and in patients with gastrointestinal disorders. Gastroenterology 1990; 99:1380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Florent C, Vidon N, Flourié B, et al. Gastric clearance of alpha-1-antitrypsin under cimetidine perfusion. New test to detect protein-losing gastropathy? Dig Dis Sci 1986; 31:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vardy PA, Lebenthal E, Shwachman H. Intestinal lymphagiectasia: a reappraisal. Pediatrics 1975; 55:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dori Y. Novel Lymphatic Imaging Techniques. Tech Vasc Interv Radiol 2016; 19:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pimpalwar S, Chinnadurai P, Chau A, et al. Dynamic contrast enhanced magnetic resonance lymphangiography: Categorization of imaging findings and correlation with patient management. Eur J Radiol 2018; 101:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biko DM, Smith CL, Otero HJ, et al. Intrahepatic dynamic contrast MR lymphangiography: initial experience with a new technique for the assessment of liver lymphatics. Eur Radiol 2019; 29:5190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yueh TC, Pui MH, Zeng SQ. Intestinal lymphangiectasia: value of Tc-99m dextran lymphoscintigraphy. Clin Nucl Med 1997; 22:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatnagar A, Lahoti D, Singh AK, et al. Scintigraphic diagnosis of protein losing enteropathy using Tc-99m dextran. Clin Nucl Med 1995; 20:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman HJ, Nimmo M. Intestinal lymphangiectasia in adults. World J Gastrointest Oncol 2011; 3:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramowsky C, Hupertz V, Kilbridge P, Czinn S. Intestinal lymphangiectasia in children: a study of upper gastrointestinal endoscopic biopsies. Pediatr Pathol 1989; 9:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           JEFFRIES GH, CHAPMAN A, SLEISENGER MH. LOW-FAT DIET IN INTESTINAL LYMPHANGIECTASIA. ITS EFFECT ON ALBUMIN METABOLISM. N Engl J Med 1964; 270:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tift WL, Lloyd JK. Intestinal lymphangiectasia. Long-term results with MCT diet. Arch Dis Child 1975; 50:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sardesai VM. The essential fatty acids. Nutr Clin Pract 1992; 7:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trumbo P, Schlicker S, Yates AA, et al. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc 2002; 102:1621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skolnik P, Eaglstein WH, Ziboh VA. Human essential fatty acid deficiency: treatment by topical application of linoleic acid. Arch Dermatol 1977; 113:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy MC, Turner WW Jr, Whatley K, Cottam GL. Topical corn oil in the management of essential fatty acid deficiency. Crit Care Med 1983; 11:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Neill JA Jr, Caldwell MD, Meng HC. Essential fatty acid deficiency in surgical patients. Ann Surg 1977; 185:535.
          </a>
         </li>
         <li class="breakAll">
          Heimburger DC, Weinsier RL. Therapeutic diets. In: Handbook of Clinical Nutrition, 3rd ed, Heimburger DC, Weinsier RL (Eds), Mosby, St. Louis 1997. p.235.
         </li>
         <li class="breakAll">
          Alpers DH, Stenson WF, Bier DM. Nutritional planning for patients with protein and calorie deficiency. In: Manual of Nutritional Therapeutics, 3rd ed, Alpers DH, Stenson WF, Bier DM (Eds), Little, Brown, and Co., Boston, MA 1995. p.265.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobs ML, Rychik J, Byrum CJ, Norwood WI Jr. Protein-losing enteropathy after Fontan operation: resolution after baffle fenestration. Ann Thorac Surg 1996; 61:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donnelly JP, Rosenthal A, Castle VP, Holmes RD. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr 1997; 130:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masetti P, Marianeschi SM, Cipriani A, et al. Reversal of protein-losing enteropathy after ligation of systemic-pulmonary shunt. Ann Thorac Surg 1999; 67:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dousset B, Legmann P, Soubrane O, et al. Protein-losing enteropathy secondary to hepatic venous outflow obstruction after liver transplantation. J Hepatol 1997; 27:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanley AJ, Gilmour HM, Ghosh S, et al. Transjugular intrahepatic portosystemic shunt as a treatment for protein-losing enteropathy caused by portal hypertension. Gastroenterology 1996; 111:1679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sunagawa T, Kinjo F, Gakiya I, et al. Successful long-term treatment with cyclosporin A in protein losing gastroenteropathy. Intern Med 2004; 43:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurolap A, Eshach-Adiv O, Hershkovitz T, et al. Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy. N Engl J Med 2017; 377:87.
          </a>
         </li>
         <li class="breakAll">
          U.S. Food and Drug Administration. FDA approves first treatment for CD55-deficient protein-losing enteropathy (CHAPLE disease). Available at https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-cd55-deficient-protein-losing-enteropathy-chaple-disease (Accessed on October 23, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mistilis SP, Skyring AP. Intestinal lymphangiectasia: Therapeutic effect of lymph venous anastomosis. Am J Med 1966; 40:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeaton P, Frierson HF Jr. Octreotide reduces enteral protein losses in Ménétrier's disease. Am J Gastroenterol 1993; 88:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballinger AB, Farthing MJ. Octreotide in the treatment of intestinal lymphangiectasia. Eur J Gastroenterol Hepatol 1998; 10:699.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4769 Version 23.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7624735" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Characterization and quantification of plasma proteins excreted in faeces from healthy humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/812754" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Synthesis rates of albumin and fibrinogen in patients with protein-losing enteropathy and in a patient recovering from protein malnutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14696443" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Significance of rapid turnover proteins in protein-losing gastroenteropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8791958" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2567373" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Protein-losing enteropathy associated with Clostridium difficile infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8783689" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Protein-losing enteropathy is associated with Clostridium difficile diarrhea but not with asymptomatic colonization: a prospective, case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1590320" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Protein-losing enteropathy with collagenous colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422947" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Gastrointestinal and hepatic manifestations of systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8823704" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Protein losing enteropathy as the initial manifestation of childhood systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Familial psychomotor retardation with markedly fluctuating serum prolactin, FSH and GH levels, partial TBG-deficiency, increased serum arylsulfatase A and increased CSF protein: a new syndrome
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11567948" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Successful treatment of carbohydrate deficient glycoprotein syndrome type 1b with oral mannose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8326297" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Lymphocytic gastritis: an unusual cause of hypoproteinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26883093" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29604290" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Intestinal Failure and Aberrant Lipid Metabolism in Patients With DGAT1 Deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30050362" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Protein-losing enteropathy and joint contractures caused by a novel homozygous ANTXR2 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8956479" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A case of the yellow nail syndrome associated with massive chylous ascites, pleural and pericardial effusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6124476" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Giant hypertrophic gastropathy (Ménétrier's disease): pharmacologic effects on protein leakage and mucosal ultrastructure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8200570" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori--is Helicobacter pylori a pathogenic factor in Ménétrier's disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8079936" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9083755" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2020657" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Lymphocytic gastritis and giant gastric folds associated with gastrointestinal protein loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9058299" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : 99mTc-HSA-D scintigraphy in the diagnosis of protein-losing gastroenteropathy due to secondary amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19789526" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Protein-losing enteropathy: case illustrations and clinical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29505002" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Case report of primary intestinal lymphangiectasia diagnosed in an octogenarian by ileal intubation and by push enteroscopy after missed diagnosis by standard colonoscopy and EGD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25804399" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The lymphatic phenotype in Turner syndrome: an evaluation of nineteen patients and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26242988" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The lymphatic phenotype in Noonan and Cardiofaciocutaneous syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2624276" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8344144" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Mifepristone/gemeprost to abort early pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2841536" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : [Exudative enteropathy in Klippel-Trenaunay syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27224999" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Protein-losing enteropathy in camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27214123" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Protein-losing enteropathy with intestinal lymphangiectasia in skeletal dysplasia with Lys650Met mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25943403" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Primary intestinal lymphangiectasia treated with rapamycin in a child with tuberous sclerosis complex (TSC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35796502" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Protein-losing enteropathy in association with gastrointestinal IgM deposition in Waldenström macroglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21349233" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1782939" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Constrictive pericarditis without typical haemodynamic changes as a cause of oedema formation due to protein-losing enteropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5847556" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Reversible protein-losing enteropathy with intestinal lymphangiectasia secondary to chronic constrictive pericarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8800155" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Protein-losing enteropathy after the Fontan operation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31205137" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Protein Losing Enteropathy due to Gut Plasmacytoma Polyposis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10488719" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Phosphomannose isomerase deficiency as a cause of congenital hepatic fibrosis and protein-losing enteropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3763551" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Protein losing enteropathy as a sole manifestation of non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12800735" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Protein-losing enteropathy: an unusual presentation of neuroblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27685423" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Secondary Combined Immunodeficiency in Pediatric Patients after the Fontan Operation: Three Case Reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26009017" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Immune Abnormalities in Fontan Protein-Losing Enteropathy: A Case-Control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/80688" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6973500" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2210245" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Alpha 1-antitrypsin excretion in stool in normal subjects and in patients with gastrointestinal disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3484447" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Gastric clearance of alpha-1-antitrypsin under cimetidine perfusion. New test to detect protein-losing gastropathy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1134884" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Intestinal lymphagiectasia: a reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27993320" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Novel Lymphatic Imaging Techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29571786" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Dynamic contrast enhanced magnetic resonance lymphangiography: Categorization of imaging findings and correlation with patient management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30887210" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Intrahepatic dynamic contrast MR lymphangiography: initial experience with a new technique for the assessment of liver lymphatics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9343726" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Intestinal lymphangiectasia: value of Tc-99m dextran lymphoscintigraphy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8674293" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Scintigraphic diagnosis of protein losing enteropathy using Tc-99m dextran.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21364842" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Intestinal lymphangiectasia in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2748490" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Intestinal lymphangiectasia in children: a study of upper gastrointestinal endoscopic biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14107315" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : LOW-FAT DIET IN INTESTINAL LYMPHANGIECTASIA. ITS EFFECT ON ALBUMIN METABOLISM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/50050" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Intestinal lymphangiectasia. Long-term results with MCT diet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1294887" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The essential fatty acids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12449285" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/406855" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Human essential fatty acid deficiency: treatment by topical application of linoleic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6404599" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Topical corn oil in the management of essential fatty acid deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/404973" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Essential fatty acid deficiency in surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/404973" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Essential fatty acid deficiency in surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/404973" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Essential fatty acid deficiency in surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8561554" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Protein-losing enteropathy after Fontan operation: resolution after baffle fenestration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9063428" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10086559" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Reversal of protein-losing enteropathy after ligation of systemic-pulmonary shunt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9252097" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Protein-losing enteropathy secondary to hepatic venous outflow obstruction after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8942750" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Transjugular intrahepatic portosystemic shunt as a treatment for protein-losing enteropathy caused by portal hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15206552" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Successful long-term treatment with cyclosporin A in protein losing gastroenteropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28657861" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28657861" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Intestinal lymphangiectasia: Therapeutic effect of lymph venous anastomosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8420282" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Octreotide reduces enteral protein losses in Ménétrier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9744700" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Octreotide in the treatment of intestinal lymphangiectasia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
